MIF098, a macrophage migration inhibitory factor (MIF) antagonist, inhibits proliferation, migration, and fibrosis in pulmonary smooth muscle cells and is applicable in immunoinflammation-related disease research[1].
体内研究
MIF098, administered via intraperitoneal injection at 40 mg/kg daily for four weeks, mitigates hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice[1].
体外研究
MIF098 (0-10 μM, 48 h) blocks the migration inhibitory factor (MIF) pathway, reducing mPASMC cell proliferation and migration in a concentration-dependent manner[1].
MIF098 also decreases collagen synthesis and pulmonary artery fibrosis by inhibiting the TGFβ1/Smad2/3 pathway[1].
MIF098 细胞实验
Cell Line
Concentration
Treated Time
Description
References
human monocytes
20 μM
30 minutes
MIF098 blocks MIF binding to its cognate receptor CD74, thereby suppressing IL-1β production and NLRP3 upregulation.
Arthritis Rheumatol. 2019 Jan;71(1):109-120
MIF098 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
UM-HET3 mice
Genetically heterogeneous mice
Dietary administration
240 ppm
Starting at 8 months of age
To test the effect of MIF098 on lifespan; results showed no significant effect on lifespan
Administered at -18h and -1h before gavage, euthanized 6h after ethanol binge
To investigate the effect of MIF098 on ethanol-induced liver injury, it was found that MIF098 reduced liver injury at 6h but exacerbated liver injury and UPR at 9h.
搜索
